Dr. Kevin Kelly, MD is a hematologist with clinical expertise in phase I investigational therapeutics and hematological malignancies, including lymphoma and multiple myeloma. His research focuses on understanding the mechanisms of resistance to chemotherapy in hematological malignancies and the use of novel agents to overcome this resistance, and he has published extensively in peer-reviewed journals. Through collaborations with a large team of scientists, he has translated preclinical discoveries into novel clinical trials including an investigator-initiated study of the phosphodiesterase 4B inhibitor, roflumilast, in B cell lymphoproliferative disorders.
USC Norris Comprehensive Cancer Center:
USC/Norris Comprehensive Cancer Center and Hospital, 1441 Eastlake Ave, Los Angeles, CA 90033, USA
Get the latest thought leadership on Myeloma delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life
Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma
Thanks to our HealthTree Community for Myeloma Sponsors: